TEPKINLY

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, Romania, United Kingdom

Active ingredients

The drug TEPKINLY contains one active pharmaceutical ingredient (API):

1 Epcoritamab UNII D6OMY2L0WA - EPCORITAMAB

Epcoritamab is a humanised IgG1-bispecific antibody that binds to a specific extracellular epitope of CD20 on B cells and to CD3 on T cells. The activity of epcoritamab is dependent upon simultaneous engagement of CD20-expressing cancer cells and CD3-expressing endogenous T cells by epcoritamab that induces specific T-cell activation and T-cell-mediated killing of CD20-expressing cells. Read about Epcoritamab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TEPKINLY Concentrate for solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX27		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX27

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3048342, 3048364
Country: FR	Base de données publique des médicaments	Identifier(s): 67307049, 69520409
Country: IT	Agenzia del Farmaco	Identifier(s): 050855016, 050855028
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097835, 1097836
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69770001, W69771001